Boston Scientific (BSX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $47.80 +1.81%
EPS Growth %: +8.0%
Financial Fact:
Selling, general and administrative expenses: 772M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +8.0%
Financial Fact:
Selling, general and administrative expenses: 772M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.86, $0.03 better than the analyst estimate of $0.83. Revenue for the quarter came in at $5.44 billion versus the consensus estimate of $5.37 billion.
GUIDANCE:
Boston Scientific sees FY2026 EPS of $3.28-$3.32, versus the consensus of $3.36.
For earnings history and earnings-related data on Boston Scientific (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral
- ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
